CBP/p300-IN-15

Modify Date: 2024-10-03 10:57:42

CBP/p300-IN-15 structure	Common Name	CBP/p300-IN-15
	CAS Number	2379409-91-1	Molecular Weight	476.52
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₆H₂₈N₄O₅	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of CBP/p300-IN-15

CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC50 values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC50 values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research[1].

Name	CBP/p300-IN-15

Description	CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC50 values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC50 values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Epigenetics >> Histone Acetyltransferase Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain
Target	CBP:28.0 nM (IC50) p300:2.50 nM (IC50)
References	[1]. Ding H, et al. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer. Bioorg Med Chem. 2021 Dec 15;52:116512.

Molecular Formula	C₂₆H₂₈N₄O₅
Molecular Weight	476.52

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Delivery: 10 Day
Contact: Yang
Email: sales@echemcloud.com

CBP/p300-IN-15

Use of CBP/p300-IN-15

Names

CBP/p300-IN-15 Biological Activity

Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.